Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $123.70 USD
Change Today +1.48 / 1.21%
Volume 404.6K
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

agios pharmaceuticals inc (AGIO) Snapshot

Open
$122.04
Previous Close
$122.22
Day High
$126.35
Day Low
$120.02
52 Week High
01/15/15 - $138.85
52 Week Low
06/3/14 - $32.66
Market Cap
4.6B
Average Volume 10 Days
533.6K
EPS TTM
$-1.33
Shares Outstanding
37.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGIOS PHARMACEUTICALS INC (AGIO)

agios pharmaceuticals inc (AGIO) Related Bloomberg News

View More Bloomberg News

agios pharmaceuticals inc (AGIO) Related Businessweek News

No Related Businessweek News Found

agios pharmaceuticals inc (AGIO) Details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK deficiency. The company has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

128 Employees
Last Reported Date: 02/24/15
Founded in 2007

agios pharmaceuticals inc (AGIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $309.0K
Chief Operating Officer
Total Annual Compensation: $375.0K
Chief Medical Officer
Total Annual Compensation: $371.4K
Chief Scientific Officer
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.

agios pharmaceuticals inc (AGIO) Key Developments

Agios Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides the Updates on its Clinical Development Programs in Collaboration with Celgene

Agios Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Total revenue was $34.2 million for the first quarter of 2015, compared to $8.4 million for the comparable period in 2014. The increase reflects revenues recognized under the company's collaboration agreement with Celgene. Net loss for the first quarter of 2015 was $5.0 million, compared to net loss of $12.2 million for the comparable period in 2014. Loss from operations was $5,195,000 against $12,284,000 a year ago. Net loss per basic and diluted share was $0.13 against $0.39 a year ago. The company provided the updates on its clinical development programs in collaboration with Celgene: AG-221: a first-in-class, oral, selective, potent inhibitor of the mutated IDH2 protein. Added Additional Cohort to AG-221's Ongoing Phase 1 Expansion Study in Hematologic Malignancies - AG-221 is currently being evaluated in an ongoing Phase 1 trial that includes a dose escalation phase and four expansion cohorts of 25 patients each evaluating patients with relapsed or refractory AML who are 60 years of age and older and transplant ineligible, relapsed or refractory AML patients under age 60, untreated AML patients who decline standard of care chemotherapy, and patients with other IDH2-mutant positive hematologic malignancies. Based on encouraging data from the dose escalation phase, Celgene and Agios have expanded the Phase 1 trial to add an additional more homogenous cohort of 125 patients with IDH2 mutant-positive AML who are in second or later relapse, refractory to second-line induction or reinduction treatment, or have relapsed after allogeneic transplantation. Consistent with the ongoing expansion cohorts, AG-221 will be administered at a dose of 100 mg once daily. This multicenter, single-arm, open-label, expanded clinical trial will be conducted at the current treatment centers in the U.S. and France. The primary objectives of the study are to confirm the safety and clinical activity of AG-221 in a select, highly resistant AML population. Agios also continues to conduct a Phase 1/2 clinical trial evaluating AG-221 in IDH2-mutant positive advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL). AG-120: a first-in-class, oral, selective, potent inhibitor of the mutated IDH1 protein - Initiated Three Expansion Cohorts in Ongoing Phase 1 Study in Hematologic Malignancies - AG-120 is currently being evaluated in an ongoing Phase 1 trial in patients with advanced hematologic malignancies. Three expansion cohorts have been added to this study and will evaluate AG-120 in 175 patients with IDH1 mutated advanced hematologic malignancies at approximately 15 clinical trial sites in the U.S. and France. The first cohort will evaluate a more homogenous population of 125 AML patients who relapsed after bone marrow transplantation, are in second or later relapse, refractory to second line induction or reinduction treatment. The second cohort will evaluate 25 untreated AML patients, and the third cohort will evaluate 25 patients with IDH1 mutated advanced hematologic malignancies not eligible for cohorts one or two. AG-120 will be administered at a 500 mg once daily oral dose, in 28-day cycles. The study's primary objectives are to confirm the safety and clinical activity of AG-120. Agios also continues to advance a Phase 1 clinical trial evaluating AG-120 in patients with IDH1-mutant positive advanced solid tumors, including glioma. Expect to initiate a Phase 2 trial for AG-348 in the first half of 2015 in patients with PK deficiency.

Agios Pharmaceuticals Inc. Announces Collaboration with Celgene Corp. to Initiate Clinical Development of AG-881 in the Second Quarter of 2015

Agios Pharmaceuticals Inc. in collaboration with its cancer metabolism partner Celgene Corp. plans to initiate clinical development of AG-881 in the second quarter of 2015. AG-881 will be the third IDH, or isocitrate dehydrogenase, mutant inhibitor discovered by Agios to enter clinical development. Under the terms of the new AG-881 collaboration, Agios will receive an initial payment of $10 million from Celgene in the second quarter of 2015 and is eligible to receive regulatory milestone payments of up to $70 million.

Agios Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

Agios Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGIO:US $123.70 USD +1.48

AGIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGIO.
View Industry Companies
 

Industry Analysis

AGIO

Industry Average

Valuation AGIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.9x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGIOS PHARMACEUTICALS INC, please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.